Abstract: A card-based package for powdered infant nutrition, comprises a container portion, the container portion defining an interior space for receiving the powdered infant nutrition and having a base and a sidewall extending to an upper peripheral edge for receiving a removable seal for hermetically sealing the container portion prior to use. The package further comprises a collar portion and a lid portion. The collar portion is connected to and extends upwardly from the upper peripheral edge of the container portion and comprises a connection segment and an upper peripheral closure rim surrounding an access opening giving access to the interior space. The lid portion comprises a lid and a frame and forms a re-closable joint with the upper peripheral closure rim of the collar portion, allowing repeated and selective opening and closing of the access opening. The container portion, the collar portion and the lid portion all comprise card-based material.

Abstract: A nutritional composition comprising sn-2 palmitic acid and lactoferrin for use in improving the gut microbiota in a human subject.

Abstract: A computer-implemented method of analyzing excreta, comprising: obtaining visual information of excreta, providing the visual information to an artificial intelligence (AI) model; processing the visual information using the AI model to determine a plurality of scales of the excreta; outputting the plurality of scales of the excreta, receiving at least one input to adjust the plurality of scales of the excreta, and providing suggestion based on the adjusted plurality of scales of the excreta.

Abstract: The present invention lies on the field of synergistic compositions for improving mineral bioaccessibility, in particular iron and/or calcium bioaccessibility. The synergistic compositions comprise lutein, casein phosphopeptide or 1,3-dioleoyl-2-palmitoylglycerol, preferably in combination with a non-digestible carbohydrate. The invention further relates to the use of the compositions in preventing and/or treating mineral deficiency and associated conditions, preferably anaemia.

Abstract: The present invention relates to nutritional compositions comprising lutein for inhibiting mast cell degranulation, thereby preventing or treating symptoms or disorders associated with mast cell degranulation. Preferably, the compositions comprise lutein and non-digestible carbohydrates, such as those selected from prebiotic oligosaccharides, human oligosaccharides and combinations thereof.

Abstract: The invention pertains to a composition for use in increasing the relative abundance of Bacteroides and Parabacteroides in the intestinal microbiota of an infant that was delivered by Caesarean section or of an infant that was exposed to antibiotics early in life (e.g. intrapartum antibiotic prophylaxis (IAP)), preferably an infant that was delivered by Caesarean section, wherein the composition comprises Bifidobacterium breve and non-digestible oligosaccharide(s).

Abstract: The invention pertains to the use of therapeutically effective amounts of (a) (i) vitamin C and/or selenium and (ii) at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof; or (b) (i) vitamin C and/or selenium and (iii) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; or (c) a combination of (i), (ii) and (iii); wherein (a), (b) or (c) optionally further comprises vitamin E, in the manufacture of a product for therapeutically improving synaptic connectivity and/or therapeutically supporting memory and/or cognitive function in a human subject in need thereof.

Abstract: The present invention concerns a composition comprising dietary fiber for use in the dietary management of methylmalonic acidemia (MMA) and/or propionic acidemia (PA), and/or for use in treating and/or reducing MMA and/or PA, and/or treating, reducing and/or preventing symptoms associated therewith.

Abstract: The invention thus pertains to the use of a composition comprising: (a) uridine or uridine phosphate; and (b) docosahexaenoic acid and/or eicosapentaenoic acid, for improving memory and/or the treatment or prevention of impaired memory function, in a subject with a mini-mental state examination of 24-26, wherein said composition is enterally administered to the subject. In the MMSE test, any score of 27 or higher (out of 30) is effectively normal. In the patients with dementia, 20-26 indicates mild dementia, 10-19 moderate dementia, and below 10 severe dementia. It was the present inventors' belief that within the group of 20-26, the memory impairment in the sub-group of 24-26 may even be reversible, as the pathological pathways have just started to develop. In this group of subjects the pathological pathways have just started to develop. Clinical studies show excellent results for this subgroup.

Abstract: A card based container has a tubular sidewall of laminate material and first and second end closures, sealed to the tubular sidewall to form a hermetically sealed package. The sidewall has an outer card layer, an inner hygienic layer and one or more sealing strips provided at an inner surface of the inner hygienic layer, located at connection locations where the sidewall seals to itself or to the respective end closures. The sealing strips include a heat-sealable polymer. The overall amount of non-paper content in the sidewall and in the package may thus be reduced.

Abstract: Provided herein is a nutritional composition having therapeutically effective amounts of a combination of (a) hydrolysed whey protein and (b) MCT for use in (i) reducing tumor growth and/or (ii) for use in improving treatment efficacy in a subject having cancer and undergoing cancer treatment.

Abstract: The invention relates to a first composition providing at least one of acetic acid or butyric acid for controlling ketosis associated with a ketogenic diet in a subject adhering to a ketogenic diet, wherein controlling ketosis involves a) administering the first composition, b) optionally administering a second composition comprising propionic acid to reduce ketone production/administering a second composition comprising propionic acid provided that blood ketone levels are above 3 mmol/L.

Abstract: The invention relates to at least one of C4 or C6 fatty acids and optionally C2 fatty acids for enhancing ketosis associated with a ketogenic diet and/or preventing and/or treating resistance to a ketogenic diet, in a subject adhering to a ketogenic diet, wherein the at least one of C4 or C6 fatty acids and optionally C2 fatty acids are comprised in a non-ketogenic ketogenic diet-booster composition, or the at least C4 or C6 fatty acids and optionally C2 fatty acids are provided in non-ketogenic amounts by a dietary fibre blend comprised in a non-ketogenic ketogenic diet-booster composition.

Abstract: The invention provides a method, system, and computer program product for determining a maturation state of an infant aged between 0 and 120 months, comprising measuring at least one microbial biomarker from a set of measurable microbial biomarkers from a faecal sample of the infant, determining a predicted age of the infant based on the at least one microbial biomarker, wherein the at least one microbial biomarker is selected from the set of measurable microbial biomarkers based on an analysis of the set of measurable microbial biomarkers as measured in faecal samples from a plurality of vaginally-born breast-fed infants at a plurality of ages, the predicted age is obtained based on an evaluation of the at least one measured microbial biomarker using a function based on a plurality of corresponding at least one biomarkers measured in the faecal samples from the plurality of vaginally-born breast-fed infants at the plurality of ages.

Abstract: The present invention relates to a fermented infant or follow on formula comprising non digestible oligosaccharides for decreasing duration of crying, reducing crying episodes, and incidence of colics in infants.

Abstract: The invention relates to a neuroprotective composition comprising therapeutically effective amounts of a combination of pyruvate and citrate, for the treatment and/or prevention of neuronal damage in a subject suffering from or at risk of seizures.

Abstract: The invention provides a method of analysing the consistency of stool, including the steps of: providing stool of an infant, capturing, with a portable device comprising a camera, an image of the stool, providing the captured image to an input layer of a pre-trained convolutional neural network, CNN, processing the captured image using the CNN to obtain, from a final layer of the CNN, a classification vector and to obtain information about a predicted score from the classification vector, wherein at least the final layer of the CNN has been customized so that each element of the classification vector corresponds to a score of a stool analysis scale, and storing information about the predicted store.

Abstract: A consortium of specific probiotic bacteria comprising Bifidobacterium bifidum and Bifidobacterium breve with specific carbohydrate degrading properties, specific human milk oligosaccharide and preferably also beta-galacto-oligosaccharides with a higher degree of polymerization, is particularly effective for improving intestinal microbiota resilience.

Abstract: The invention pertains to a solid composition suitable for treating adult animals that suffer from brain-related disorders, brain-related decline or brain-related diseases, preferably suitable for treating adult animals that suffer from brain-related disorders, the composition containing (i) a uridine source, wherein the amount of the sum of all uridine sources, calculated on the basis of the weight of the molar equivalent of uridine monophosphate (UMP), is 0.3-15 g per 100 g dry weight of the composition, (ii) a polyunsaturated fatty acid, preferably an omega-3 polyunsaturated fatty acid, (iii) choline bitartrate, (iv) a buffering salt component, and (v) a milk protein source, wherein the milk protein source is a milk powder, and the buffering salt component containing at least one food approved salt, with a buffering capacity between pH 5-8, the buffering salt component preferably containing a mixture of food-approved salts, or a food-approved salt and its conjugated acid or base.

Abstract: Electronic device for estimating a height of a human, the electronic device comprising: a processor configured to: obtain an image including at least a part of a representation of the human and reference information; input the image to a first neural network and obtain as output from the first neural network first information, the first information related to a plurality of keypoints in the body of the human; input the image to a second neural network and obtain as output from the second neural network second information, the second information related to the reference information; and estimate the height of the human based on the first information and the second information; and an output unit configured to output the estimated height.